Shionogi & Co. Ltd. has synthesized spiroheterocycle derivatives acting as 5-HT2A and 5-HT2C receptor antagonists and/or inverse agonists reported to be useful for the treatment of neurodegeneration.

Psychedelics activate the 5-HT2A receptor, upregulate brain-derived neurotrophic factor, and enhance synaptic plasticity, leading to therapeutic potential for stress and psychiatric disorders. Credit ...

A new study provides a detailed look at how the psychedelic compound psilocin acts on specific neurons within the brain. The ...

Image of a cortical neuron (white) expressing serotonin 2A (5-HT2A) receptors (multicolor). New work shows that engaging 5-HT2A receptors inside cells, but not on the cell surface, encourages cell ...

2A Biosciences Inc. has divulged compounds acting as 5-HT2A and 5-HT2C receptor agonists reported to be useful for the treatment of atopic dermatitis, conjunctivitis, Crohn’s disease, type 2 diabetes, ...

This article was originally published on Psychedelic Spotlight and appears here with permission. New study suggests that a non-hallucinogenic LSD analog may hold therapeutic potential for mood ...

STUART, Fla.--(BUSINESS WIRE)--Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest ...

SAN DIEGO, Calif.--By using positron emission tomography (PET) to study the brain's neuroreceptors in relation to obesity, scientists may be getting closer to determining important information about ...

The human brain can change — but usually only slowly and with great effort, such as when learning a new sport or foreign language or recovering from a stroke. Learning new skills correlates with ...

SEATTLE, WA and IRVINE, CA / ACCESSWIRE / October 5, 2023 / Küleon LLC, a private biotechnology company that has built the industry's largest library of serotonergic drugs exhibiting G protein-biased ...

SEATTLE--(BUSINESS WIRE)--Küleon LLC, a preclinical-stage biotechnology company building a best-in-class library of selective, G-protein-biased serotonergic medicines, today announced it has been ...